Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-08-11
1999-10-26
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 530300, 530324, 530326, 530327, 530328, 530329, 530330, 530350, 530380, 530381, A61K 3514, A61K 3800, A61K 3804, C07K 100
Patent
active
059728965
ABSTRACT:
Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
REFERENCES:
patent: 5407673 (1995-04-01), Reich et al.
patent: 5512591 (1996-04-01), Halperin et al.
Scrip 2120:21 (Apr. 16, 1996).
Fidler, I.J., et al., "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis",Cell, 79:185-188 (1994).
Folkman, J., "Clinical Applications of Research on Angiogenesis", The New England Journal of Medicine, 333(26):1757-1763 (1995).
Folkman, J., et al., "Angiogenesis", Journ. of Biological Chemistry, 267(16):10931-10934 (1992).
Folkman, J., et al., "Angiogenic Factors", Science, 235:442-447 (1987).
Gasparini, G., et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool", Journ. of Clinical Oncology, 13(3):765-782 (1995).
Sottrup-Jensen, L., et al., "The Primary Structure of Human Plasminogen: Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", Progress in Chemical Fibrinolysis and Thrombolysis, 3:191-209 (1978).
Kolberg, R., "Angogenic Inhibitor Loss May Be Key To Post-Surgery Metastasis", Journal of NIH Research, 8:31-33 (1994).
Menhart, N., et al., "Functional Independence of the Kringle 4 and Kringle 5 Regions of Human Plasminogen", Biochemistry, 32:8799-8806 (1993).
Novokhatny, V. V., et al., "Domains in Human Plasminogen", J. Mol. Biol., 179:215-232 (1984).
O'Reilly, M. S., et al., "Angioslatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", Cell, 79:315-328 (1994).
Teicher, B. A., et al., "Antiangiogenic Agents Can Increase Tumor Oxygenation and Response to Radiation Therapy", Radiation Oncology Investigations, 2:269-276 (1995).
Teicher, B. A., et al., "Antiangiogenic Agents Potentiate Cytotoxic Cancer Therapies against Primary and Metastic Disease", Cancer Research, 52:6702-6704 (1992).
Teicher, B. A., et al., "Antiangiogenic Treatment (TNP-470/Minocycline) Increases Tissue Levels of Anticancer Drugs in Mice Bearing Lewis Lung Carcinoma", Oncology Research, 7(5):237-243 (1995).
Teicher, B. A., et al., ".beta.-Cyclodextrin tetradecasulfate/tetrahydrocortisol +monocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic lewis lung carcinoma", Cancer Chemother Pharmacol, 33:229-239 (1993).
Teicher, B. A., et al., "Influence of an Anti-Angiogenic Treatment on 9L Gliosarcoma: Oxygenation and Response to Cytotoxic Therapy", Int. J. Cancer, 61:732-737 (1995).
Teicher, B. A., et al., "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents", Int. J. Cancer, 57:920-925 (1994).
Teicher, B. A. et al., "Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMI-6 mammary carcinoma", Breast Cancer Research and Treatment, 36:227-236 (1995).
Thewest, T., et al., "Ligand Interactions with the Kringle 5 Domain of Plasminogen", Journal of Biological Chemistry, 265(7):3906-3915 (1990).
Weidner, N., et al., "Tumor Angiogenesis and Metastasis--Correlation in Invasive Breast Carcinoma", The New England Journal of Medicine, 324(1):1-8 (1991).
Thewes, T., et al., "Ligand Interactions with the Kringle 5 Domain of Plasminogen", Journal of Biological Chemistry, 265(7):3906-3915 (1990).
Varadi, A., et al., "Kringle 5 of human plasminogen carries a benzamidine-binding site", Biochemical and biophysical Research Communications, 103:97-102 (1981).
Weidner, N., et al., "Tumor Angiogenesis and Metastasis--Correlation in Invasive Breast Carcinoma", The New England Journal of Medicine, 324(1):1-8 (1991).
McCance, S., et al., "Amino acid residues of the Kringel-4 and Kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands", Journal of Biological Chemistry, 269:32405-32410 (1994).
Thewes, et al., "Isolation, purification and 1H-NMR characterization of a kringle 5 domain fragment for human plasminogen", Database Medline, 1987.
Varadi, A., et al., "Kringel 5 of human plasminogen carries a benzamidine-binding site", Biochemical and Biophysical Research Communications, 103:97-102 (1981).
Abbott Laboratories
Casuto Dianne
Steele Gregory W.
Stole Einar
Wax Robert A.
LandOfFree
Antiangiogenic peptides and methods for inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiangiogenic peptides and methods for inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiangiogenic peptides and methods for inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764512